Columbia Laboratories (CBRX) 6.60 $CBRX
Shares of CBRX Up 19.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 06, 11:09AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 9 months, Columbia Laboratories has returned 19.11% as of today's recent price of $6.70.
Columbia Laboratories reports lower net income of USD0.4m in Q1 2014
M2 - Wed Apr 30, 5:23AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) announced on Tuesday its net income of USD0.4m (USD0.01 per diluted share) for the three-month period ended 31 March 2014.
Uptrend Call Working As Columbia Laboratories Stock Rises 21.8% (CBRX)
Comtex SmarTrend(R) - Tue Apr 29, 9:46AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 9 months, Columbia Laboratories has returned 21.78% as of today's recent price of $6.85.
Columbia Laboratories Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 5:50AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
today announced financial results for the three-month period ended March 31, 2014.
Columbia Laboratories Has Returned 19.3% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Apr 22, 9:16AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 9 months, Columbia Laboratories has returned 19.29% as of today's recent price of $6.71.
Columbia Laboratories to Discuss First Quarter 2014 Financial Results on April 29th Conference Call
PR Newswire - Thu Apr 17, 5:50AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows:
Molecular Profiles Strengthens US Presence To Drive Growth
PR Newswire - Tue Apr 15, 4:00AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales.
Columbia Laboratories Has Returned 21.2% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Thu Apr 10, 5:00PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 8 months, Columbia Laboratories has returned 21.24% as of today's recent price of $6.82.
Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204
PR Newswire - Tue Apr 08, 8:00AM CDT
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the commercial manufacturing process for ETI-204, an anthrax antitoxin currently undergoing Phase 3 clinical trials in healthy volunteers.
Molecular Profiles Expands Technology With GMP Hot Melt Extrusion
PR Newswire - Tue Apr 08, 4:00AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficult-to-progress molecules.
Columbia Laboratories Up 27.1% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Thu Mar 27, 9:43AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 8 months, Columbia Laboratories has returned 27.11% as of today's recent price of $7.15.
Uptrend Call Working As Columbia Laboratories Stock Rises 32.6% (CBRX)
Comtex SmarTrend(R) - Thu Mar 20, 9:17AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 32.62% as of today's recent price of $7.46.
Columbia Laboratories Shares Up 27.8% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Wed Mar 12, 5:02PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 27.82% as of today's recent price of $7.19.
Columbia Laboratories announces buy back of 1.4m common shares
M2 - Mon Mar 10, 4:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) revealed on Friday the repurchase of 1.4m shares of its common stock.
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis
PR Newswire - Fri Mar 07, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Columbia Laboratories posts lesser net income of USD6.7m in 2013
M2 - Thu Mar 06, 4:41AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) disclosed on Wednesday its net income of USD6.7m (USD0.59 per basic & USD0.52 per diluted share) for the 12 month periods ended 31 December 2013.
Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 05, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the three- and twelve-month periods ended December 31, 2013.
Columbia Laboratories adds Donald H. Hunter to board
M2 - Tue Mar 04, 5:20AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Monday that Donald H. Hunter has been elected to its board of directors as well as to its audit committee.
Shares of CBRX Up 19.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 06, 11:09AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 9 months, Columbia Laboratories has returned 19.11% as of today's recent price of $6.70.
Columbia Laboratories reports lower net income of USD0.4m in Q1 2014
M2 - Wed Apr 30, 5:23AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) announced on Tuesday its net income of USD0.4m (USD0.01 per diluted share) for the three-month period ended 31 March 2014.
Uptrend Call Working As Columbia Laboratories Stock Rises 21.8% (CBRX)
Comtex SmarTrend(R) - Tue Apr 29, 9:46AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 9 months, Columbia Laboratories has returned 21.78% as of today's recent price of $6.85.
Columbia Laboratories Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 5:50AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
today announced financial results for the three-month period ended March 31, 2014. Columbia Laboratories Has Returned 19.3% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Tue Apr 22, 9:16AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 9 months, Columbia Laboratories has returned 19.29% as of today's recent price of $6.71.
Columbia Laboratories to Discuss First Quarter 2014 Financial Results on April 29th Conference Call
PR Newswire - Thu Apr 17, 5:50AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows:
Molecular Profiles Strengthens US Presence To Drive Growth
PR Newswire - Tue Apr 15, 4:00AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales.
Columbia Laboratories Has Returned 21.2% Since SmarTrend Recommendation (CBRX)
Comtex SmarTrend(R) - Thu Apr 10, 5:00PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 8 months, Columbia Laboratories has returned 21.24% as of today's recent price of $6.82.
Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204
PR Newswire - Tue Apr 08, 8:00AM CDT
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the commercial manufacturing process for ETI-204, an anthrax antitoxin currently undergoing Phase 3 clinical trials in healthy volunteers.
Molecular Profiles Expands Technology With GMP Hot Melt Extrusion
PR Newswire - Tue Apr 08, 4:00AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficult-to-progress molecules.
Columbia Laboratories Up 27.1% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Thu Mar 27, 9:43AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 8 months, Columbia Laboratories has returned 27.11% as of today's recent price of $7.15.
Uptrend Call Working As Columbia Laboratories Stock Rises 32.6% (CBRX)
Comtex SmarTrend(R) - Thu Mar 20, 9:17AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 32.62% as of today's recent price of $7.46.
Columbia Laboratories Shares Up 27.8% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Wed Mar 12, 5:02PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 7 months, Columbia Laboratories has returned 27.82% as of today's recent price of $7.19.
Columbia Laboratories announces buy back of 1.4m common shares
M2 - Mon Mar 10, 4:06AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) revealed on Friday the repurchase of 1.4m shares of its common stock.
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis
PR Newswire - Fri Mar 07, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Columbia Laboratories posts lesser net income of USD6.7m in 2013
M2 - Thu Mar 06, 4:41AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) disclosed on Wednesday its net income of USD6.7m (USD0.59 per basic & USD0.52 per diluted share) for the 12 month periods ended 31 December 2013.
Columbia Laboratories Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 05, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results of the three- and twelve-month periods ended December 31, 2013.
Columbia Laboratories adds Donald H. Hunter to board
M2 - Tue Mar 04, 5:20AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Monday that Donald H. Hunter has been elected to its board of directors as well as to its audit committee.
